Advances in Therapeutic Approaches Targeting Pediatric and Adult Glioma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 November 2025 | Viewed by 1357
Special Issue Editors
Interests: macrophages; checkpoint inhibitors; phagocytosis; glioma; medulloblastoma; immune evasion
Special Issue Information
Dear Colleagues,
Gliomas are the most common type of brain tumor in children and adults arising from glial cells that support the nerve cells of the brain and the spinal cord. Independently, whether classified as less aggressive slow-growing low-grade glioma or their high-grade counterparts, most gliomas remain incurable, despite decades of extensive research. Therefore, novel treatment strategies are urgently needed. Advancements in intraoperative technologies (such as fluorescence-guided surgery and intraoperative monitoring) have significantly advanced the extent and safety of tumor resection. Furthermore, recent genetic, molecular, tumor microenvironment, and immune characterization studies on glioma have not only provided comprehensive knowledge of the disease, but also paved the way for new treatment options. This Special Issue of Cancers provides a platform for experts to present original research and reviews that aim to address the current information and advancements on therapeutic approaches targeting pediatric and adult glioma.
We look forward to your contributions.
Dr. Siddhartha Mitra
Dr. Senthilnath Lakshmanachetty
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma
- high-grade glioma
- glioblastoma
- DIPG
- ependymoma
- immunotherapy
- targeted therapy
- combination therapies
- small-molecule inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
